BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 29455659)

  • 1. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
    Montor WR; Salas AROSE; Melo FHM
    Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
    Ghosh S; Marrocco I; Yarden Y
    Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.
    Jiang W; Ji M
    Semin Cancer Biol; 2019 Dec; 59():3-22. PubMed ID: 30943434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.
    Huang XL; Khan MI; Wang J; Ali R; Ali SW; Zahra QU; Kazmi A; Lolai A; Huang YL; Hussain A; Bilal M; Li F; Qiu B
    Int J Biol Macromol; 2021 Jun; 180():739-752. PubMed ID: 33737188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Resistance Is Oncogene and Drug Agnostic.
    Doebele RC
    Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
    Sáez JM
    Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.
    Sheffels E; Kortum RL
    J Med Chem; 2021 May; 64(10):6566-6568. PubMed ID: 33961431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P
    Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
    Sakle NS; More SA; Dhawale SA; Mokale SN
    Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Targeted Therapy for Tumors with
    Kheder ES; Hong DS
    Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to drugs targeting receptor tyrosine kinases.
    Rosenzweig SA
    Biochem Pharmacol; 2012 Apr; 83(8):1041-8. PubMed ID: 22227013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
    Iida M; Harari PM; Wheeler DL; Toulany M
    Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.
    Narayanan R; Yepuru M; Coss CC; Wu Z; Bauler MN; Barrett CM; Mohler ML; Wang Y; Kim J; Snyder LM; He Y; Levy N; Miller DD; Dalton JT
    PLoS One; 2013; 8(12):e83380. PubMed ID: 24386191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of receptor tyrosine kinase activation in cancer.
    Du Z; Lovly CM
    Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
    Herr R; Halbach S; Heizmann M; Busch H; Boerries M; Brummer T
    Oncogene; 2018 Mar; 37(12):1576-1593. PubMed ID: 29326440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.